Cholesterol’s Role in Cancer Progression and Drug Resistance
A recent study published in Cell Death & Disease reveals a novel molecular mechanism linking cholesterol metabolism to tumor progression and therapy resistance in thyroid cancer. Researchers found that a decline in the protein RTN3 leads to the stabilization of DHCR7, a key enzyme in cholesterol synthesis. This results in increased intracellular cholesterol, which fuels tumor growth and, critically, induces insensitivity to MEK inhibitors, a class of targeted cancer drugs. This discovery highlights a metabolic vulnerability that could be exploited to overcome treatment resistance in certain cancers.
Study Significance: For hematologists and oncologists, this research underscores the importance of tumor microenvironment and metabolic pathways like cholesterol synthesis in cancer biology. Understanding how cholesterol-dependent mechanisms confer resistance to targeted therapies, such as MEK inhibitors, provides a new axis for therapeutic intervention. This could lead to the development of combination strategies that target both the primary oncogenic driver and the supportive metabolic network to improve outcomes in hematologic and solid malignancies.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
